Eleven Biotherap (EBIO) Misses Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts EBIO Hot Sheet
Join SI Premium – FREE
Eleven Biotherap (NASDAQ: EBIO) reported Q3 EPS of ($0.66), $0.22 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $539 thousand versus the consensus estimate of $700 thousand.
For earnings history and earnings-related data on Eleven Biotherap (EBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- AMTD Digital reports $1.2B in total assets, $42.4M profit
- AI-powered cyber threats light a fire under cybersecurity stocks
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
